Welcome to our dedicated page for Nucana news (Ticker: NCNA), a resource for investors and traders seeking the latest updates and insights on Nucana stock.
NuCana plc develops cancer medicines based on its proprietary ProTide technology, with news centered on the ADR-listed clinical-stage biopharmaceutical company’s oncology pipeline and corporate updates. Recurring releases describe NUC-7738, a novel anti-cancer agent being studied as a monotherapy in advanced solid tumors and with pembrolizumab in melanoma, and NUC-3373, a 5-fluorouracil-derived new chemical entity being studied with pembrolizumab and docetaxel in advanced solid tumors and lung cancer.
Company updates also cover clinical and translational data presentations, patent protection for NUC-7738, quarterly and annual financial results, cash runway commentary, executive and board changes, and Nasdaq continued-listing matters for NuCana’s American depositary shares.
NuCana announced initial data from its Phase 1b/2 study of NUC-3373 in combination therapies. In Module 1, combining NUC-3373 with pembrolizumab showed promising results in 12 advanced solid tumor patients, achieving a 22% objective response rate and 67% disease control rate. Notable cases included a bladder cancer patient achieving 100% target lesion reduction and a melanoma patient showing 81% reduction. In Module 2, NUC-3373 with docetaxel demonstrated extended stable disease in lung cancer patients, with one achieving stability for over 13 months. The combinations were generally well-tolerated, though Module 2 enrollment was paused due to docetaxel-related toxicity concerns.
NuCana plc (NASDAQ: NCNA) has announced the issuance of a new composition-of-matter patent for NUC-7738 by the United States Patent and Trademark Office (USPTO). This patent (US12,054,510) is a important addition to NUC-7738's intellectual property protection, which now includes over 80 issued patents worldwide.
NUC-7738, a novel anti-cancer agent, is currently in a Phase 2 clinical study combined with pembrolizumab for PD-1 inhibitor resistant melanoma patients. Recent data presented at the ESMO Congress 2024 showed encouraging results, with the majority of patients achieving a progression-free survival of more than 5 months, compared to the current standard of care of 2-3 months.
Hugh S. Griffith, NuCana's CEO, emphasized the importance of this patent in strengthening NUC-7738's intellectual property protection and highlighted its potential to make previously resistant tumors sensitive to PD-1 inhibitor rechallenge.
NuCana plc (NASDAQ: NCNA) presented final data from the Phase 2 NuTide:701 study at the ESMO Congress 2024, showcasing encouraging results for NUC-7738 in combination with pembrolizumab for metastatic melanoma patients refractory to or relapsed on prior PD-1 inhibitor therapy. The study, involving 12 patients, demonstrated a 75% disease control rate, including two partial responses. Notably, 7 out of 12 patients achieved progression-free survival exceeding five months, which is significant for this patient population. The combination therapy also exhibited a favorable safety profile. NUC-7738's mechanism of action, targeting multiple aspects of the tumor microenvironment, is believed to sensitize PD-1 resistant tumors to rechallenge with PD-1 inhibitors.
NuCana plc (NASDAQ: NCNA) announced the discontinuation of its NuTide:323 study following a pre-planned analysis and recommendation from the Steering Committee. The study, which aimed to develop NUC-3373 as a replacement for 5-FU in second-line colorectal cancer treatment, was unlikely to achieve its primary objective of superior Progression Free Survival compared to the control arm.
Despite this setback, NuCana remains committed to its ongoing development programs. The company will continue with the NuTide:701 and NuTide:303 studies, focusing on NUC-7738 in combination with pembrolizumab. Encouraging data from these studies will be presented at the ESMO Annual Conference in September 2024.
NuCana plc (NASDAQ: NCNA) reported Q2 2024 financial results and provided a business update. Key points include:
- Cash and cash equivalents of £11.6 million as of June 30, 2024
- Net loss of £7.0 million for Q2 2024
- Loss per ordinary share of £0.12
The company is advancing clinical programs for NUC-3373 (ProTide transformation of 5-FU) and NUC-7738 (ProTide transformation of 3'-deoxyadenosine). Multiple data readouts are expected in H2 2024, including updates from Phase 2 studies in colorectal cancer and melanoma. NuCana anticipates its cash runway to extend into Q1 2025.
NuCana (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will present at the Jefferies Global Healthcare Conference on June 6, 2024, at 12:30 PM EDT in New York, NY. The presentation will be webcast live and made available for replay in the Investors section of the NuCana website.
NuCana (Nasdaq: NCNA) announced that CEO Hugh Griffith and CFO Don Munoz will present at TD Cowen’s 5th Annual Oncology Innovation Summit on May 28, 2024, at 8:30 AM EDT. This virtual event will offer insights related to ASCO & EHA. The live webcast and replay will be accessible through the Investors section of NuCana's website.
NuCana (NASDAQ: NCNA) has released its financial results for Q1 2024, ending March 31, 2024. The company reported a net loss of £6.8 million, an improvement from £7.9 million in Q1 2023. Cash and cash equivalents stood at £12.9 million, down from £17.2 million at the end of 2023. Loss per share was £0.13, reduced from £0.15 in the comparable period.
Key developments include the full enrollment of a Phase 2 study involving 182 colorectal cancer patients and encouraging results from NUC-7738 combined with pembrolizumab in patients resistant to PD-1 inhibitors. NuCana's clinical programs, including NUC-3373 and NUC-7738, are on track for significant data readouts in 2024. The company expects its cash runway to extend into Q1 2025.
NuCana aims to announce multiple clinical data points in 2024, focusing on metastatic colorectal cancer and melanoma treatments.
NuCana plc (NASDAQ: NCNA) has announced that it has regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Stock Market. The company had previously been notified of non-compliance due to its closing bid price falling below $1.00 for 30 consecutive business days. However, after maintaining a minimum closing bid price of $1.00 or more for 10 consecutive business days, NuCana has now met the requirement, as confirmed by a Notification Letter from Nasdaq.
Summary not available.